Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

A fatty acid oxidation-dependent metabolic shift regulates the adaptation of BRAF-mutated melanoma to MAPK inhibitors.

Aloia A, Müllhaupt D, Chabbert CD, Eberhart T, Flueckiger S, Vukolic A, Eichhoff OM, Irmisch A, Alexander LT, Scibona E, Frederick DT, Miao B, Tian T, Cheng C, Kwong LN, Wei Z, Sullivan RJ, Boland GM, Herlyn M, Flaherty KT, Zamboni N, Dummer R, Zhang G, Levesque MP, Krek W, Kovacs WJ.

Clin Cancer Res. 2019 Aug 2. pii: clincanres.0253.2019. doi: 10.1158/1078-0432.CCR-19-0253. [Epub ahead of print]

PMID:
31375515
2.

PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance.

Verma V, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, Nandre R, Gaur P, Lopez J, Sade-Feldman M, Yizhak K, Bjorgaard SL, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hammond SA, Tan M, Qi J, Wong P, Merghoub T, Wolchok J, Hacohen N, Janik JE, Mkrtichyan M, Gupta S, Khleif SN.

Nat Immunol. 2019 Sep;20(9):1231-1243. doi: 10.1038/s41590-019-0441-y. Epub 2019 Jul 29.

PMID:
31358999
3.

The Patient Speaks: Importance of Patient Perspectives in Clinical Decision-Making.

McKinley SK, Boland GM.

Ann Surg Oncol. 2019 Sep;26(9):2665-2666. doi: 10.1245/s10434-019-07575-6. Epub 2019 Jun 27. No abstract available.

PMID:
31250344
4.

Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.

Chow MT, Ozga AJ, Servis RL, Frederick DT, Lo JA, Fisher DE, Freeman GJ, Boland GM, Luster AD.

Immunity. 2019 Jun 18;50(6):1498-1512.e5. doi: 10.1016/j.immuni.2019.04.010. Epub 2019 May 13.

PMID:
31097342
5.

Lineage Tracing in Humans Enabled by Mitochondrial Mutations and Single-Cell Genomics.

Ludwig LS, Lareau CA, Ulirsch JC, Christian E, Muus C, Li LH, Pelka K, Ge W, Oren Y, Brack A, Law T, Rodman C, Chen JH, Boland GM, Hacohen N, Rozenblatt-Rosen O, Aryee MJ, Buenrostro JD, Regev A, Sankaran VG.

Cell. 2019 Mar 7;176(6):1325-1339.e22. doi: 10.1016/j.cell.2019.01.022. Epub 2019 Feb 28.

PMID:
30827679
6.

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N.

Cell. 2019 Jan 10;176(1-2):404. doi: 10.1016/j.cell.2018.12.034. No abstract available.

7.

Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.

Lu H, Liu S, Zhang G, Wu B, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W.

Nature. 2019 Jan;565(7738):E4. doi: 10.1038/s41586-018-0814-7.

PMID:
30532003
8.

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N.

Cell. 2018 Nov 1;175(4):998-1013.e20. doi: 10.1016/j.cell.2018.10.038. Erratum in: Cell. 2019 Jan 10;176(1-2):404.

PMID:
30388456
9.

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.

Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, Ashenberg O, Ott PA, Buchbinder EI, Haq R, Hodi FS, Boland GM, Sullivan RJ, Frederick DT, Miao B, Moll T, Flaherty KT, Herlyn M, Jenkins RW, Thummalapalli R, Kowalczyk MS, Cañadas I, Schilling B, Cartwright ANR, Luoma AM, Malu S, Hwu P, Bernatchez C, Forget MA, Barbie DA, Shalek AK, Tirosh I, Sorger PK, Wucherpfennig K, Van Allen EM, Schadendorf D, Johnson BE, Rotem A, Rozenblatt-Rosen O, Garraway LA, Yoon CH, Izar B, Regev A.

Cell. 2018 Nov 1;175(4):984-997.e24. doi: 10.1016/j.cell.2018.09.006.

PMID:
30388455
10.

Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.

Zhang G, Wu LW, Mender I, Barzily-Rokni M, Hammond MR, Ope O, Cheng C, Vasilopoulos T, Randell S, Sadek N, Beroard A, Xiao M, Tian T, Tan J, Saeed U, Sugarman E, Krepler C, Brafford P, Sproesser K, Murugan S, Somasundaram R, Garman B, Wubbenhorst B, Woo J, Yin X, Liu Q, Frederick DT, Miao B, Xu W, Karakousis GC, Xu X, Schuchter LM, Mitchell TC, Kwong LN, Amaravadi RK, Lu Y, Boland GM, Wei Z, Nathanson K, Herbig U, Mills GB, Flaherty KT, Herlyn M, Shay JW.

Clin Cancer Res. 2018 Oct 1;24(19):4771-4784. doi: 10.1158/1078-0432.CCR-17-2773. Epub 2018 Mar 21.

PMID:
29563139
11.

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.

Singleton KR, Crawford L, Tsui E, Manchester HE, Maertens O, Liu X, Liberti MV, Magpusao AN, Stein EM, Tingley JP, Frederick DT, Boland GM, Flaherty KT, McCall SJ, Krepler C, Sproesser K, Herlyn M, Adams DJ, Locasale JW, Cichowski K, Mukherjee S, Wood KC.

Cell Rep. 2017 Dec 5;21(10):2796-2812. doi: 10.1016/j.celrep.2017.11.022.

12.

Lymphatic versus Hematogenous Melanoma Metastases: Support for Biological Heterogeneity without Clear Clinical Application.

Kasumova GG, Haynes AB, Boland GM.

J Invest Dermatol. 2017 Dec;137(12):2466-2468. doi: 10.1016/j.jid.2017.08.029.

13.

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.

Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, Sorrentino JA, Bisi JE, Lizotte PH, Merlino AA, Quinn MM, Bufe LE, Yang A, Zhang Y, Zhang H, Gao P, Chen T, Cavanaugh ME, Rode AJ, Haines E, Roberts PJ, Strum JC, Richards WG, Lorch JH, Parangi S, Gunda V, Boland GM, Bueno R, Palakurthi S, Freeman GJ, Ritz J, Haining WN, Sharpless NE, Arthanari H, Shapiro GI, Barbie DA, Gray NS, Wong KK.

Cancer Discov. 2018 Feb;8(2):216-233. doi: 10.1158/2159-8290.CD-17-0915. Epub 2017 Nov 3.

14.

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA.

Cancer Discov. 2018 Feb;8(2):196-215. doi: 10.1158/2159-8290.CD-17-0833. Epub 2017 Nov 3.

15.

Resistance to checkpoint blockade therapy through inactivation of antigen presentation.

Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, Bjorgaard SL, Hammond MR, Vitzthum H, Blackmon SM, Frederick DT, Hazar-Rethinam M, Nadres BA, Van Seventer EE, Shukla SA, Yizhak K, Ray JP, Rosebrock D, Livitz D, Adalsteinsson V, Getz G, Duncan LM, Li B, Corcoran RB, Lawrence DP, Stemmer-Rachamimov A, Boland GM, Landau DA, Flaherty KT, Sullivan RJ, Hacohen N.

Nat Commun. 2017 Oct 26;8(1):1136. doi: 10.1038/s41467-017-01062-w.

16.

Atypical ALK-positive Spitz tumors with 9p21 homozygous deletion: Report of two cases and review of the literature.

Rand AJ, Flejter WL, Dowling CA, Brooke LM, Boland GM, Kroshinsky D, Rosenblum IR, Hernandez-Perez M, Reimann JDR.

J Cutan Pathol. 2018 Feb;45(2):136-140. doi: 10.1111/cup.13057. Epub 2017 Nov 28. Review.

PMID:
29028122
17.

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.

Lu H, Liu S, Zhang G, Bin Wu, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W.

Nature. 2017 Oct 5;550(7674):133-136. doi: 10.1038/nature24040. Epub 2017 Sep 27. Erratum in: Nature. 2019 Jan;565(7738):E4.

18.

Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells.

Vitiello M, Tuccoli A, D'Aurizio R, Sarti S, Giannecchini L, Lubrano S, Marranci A, Evangelista M, Peppicelli S, Ippolito C, Barravecchia I, Guzzolino E, Montagnani V, Gowen M, Mercoledi E, Mercatanti A, Comelli L, Gurrieri S, Wu LW, Ope O, Flaherty K, Boland GM, Hammond MR, Kwong L, Chiariello M, Stecca B, Zhang G, Salvetti A, Angeloni D, Pitto L, Calorini L, Chiorino G, Pellegrini M, Herlyn M, Osman I, Poliseno L.

Oncotarget. 2017 Apr 11;8(15):25395-25417. doi: 10.18632/oncotarget.15915.

19.

The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy.

Raigani S, Cohen S, Boland GM.

Curr Oncol Rep. 2017 Mar;19(3):17. doi: 10.1007/s11912-017-0575-8. Review.

PMID:
28251494
20.

Metastatic melanoma with spontaneous complete regression of a thick primary lesion.

Khosravi H, Akabane AL, Alloo A, Nazarian RM, Boland GM.

JAAD Case Rep. 2016 Dec 3;2(6):439-441. eCollection 2016 Nov. No abstract available.

21.

Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma.

Roland CL, Boland GM, Demicco EG, Lusby K, Ingram D, May CD, Kivlin CM, Watson K, Al Sannaa GA, Wang WL, Ravi V, Pollock RE, Lev D, Cormier JN, Hunt KK, Feig BW, Lazar AJ, Torres KE.

JAMA Surg. 2016 Apr;151(4):347-54. doi: 10.1001/jamasurg.2015.4205.

22.

Principles of Melanoma Staging.

Boland GM, Gershenwald JE.

Cancer Treat Res. 2016;167:131-48. doi: 10.1007/978-3-319-22539-5_5. Review.

PMID:
26601861
23.

Melanoma: Advances in Targeted Therapy and Molecular Markers.

DePeralta DK, Boland GM.

Ann Surg Oncol. 2015 Oct;22(11):3451-8. doi: 10.1245/s10434-015-4702-1. Epub 2015 Jul 30. Review.

PMID:
26224403
24.

Clinical next generation sequencing to identify actionable aberrations in a phase I program.

Boland GM, Piha-Paul SA, Subbiah V, Routbort M, Herbrich SM, Baggerly K, Patel KP, Brusco L, Horombe C, Naing A, Fu S, Hong DS, Janku F, Johnson A, Broaddus R, Luthra R, Shaw K, Mendelsohn J, Mills GB, Meric-Bernstam F.

Oncotarget. 2015 Aug 21;6(24):20099-110.

25.

Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma.

Kwong LN, Boland GM, Frederick DT, Helms TL, Akid AT, Miller JP, Jiang S, Cooper ZA, Song X, Seth S, Kamara J, Protopopov A, Mills GB, Flaherty KT, Wargo JA, Chin L.

J Clin Invest. 2015 Apr;125(4):1459-70. doi: 10.1172/JCI78954. Epub 2015 Feb 23.

26.

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.

Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA.

J Invest Dermatol. 2015 Feb;135(2):508-515. doi: 10.1038/jid.2014.366. Epub 2014 Aug 22.

27.

The role of surgeons in building a personalized medicine program.

Boland GM, Meric-Bernstam F.

J Surg Oncol. 2015 Jan;111(1):3-8. doi: 10.1002/jso.23684. Epub 2014 Jun 25. Review.

28.

Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value.

Demicco EG, Boland GM, Brewer Savannah KJ, Lusby K, Young ED, Ingram D, Watson KL, Bailey M, Guo X, Hornick JL, van de Rijn M, Wang WL, Torres KE, Lev D, Lazar AJ.

Histopathology. 2015 Apr;66(5):627-38. doi: 10.1111/his.12466. Epub 2015 Jan 12.

29.

Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer.

Boland GM, Chang GJ, Haynes AB, Chiang YJ, Chagpar R, Xing Y, Hu CY, Feig BW, You YN, Cormier JN.

Cancer. 2013 Apr 15;119(8):1593-601. doi: 10.1002/cncr.27935. Epub 2012 Dec 21.

30.

Merkel cell carcinoma: 30-year experience from a single institution.

Santamaria-Barria JA, Boland GM, Yeap BY, Nardi V, Dias-Santagata D, Cusack JC Jr.

Ann Surg Oncol. 2013 Apr;20(4):1365-73. doi: 10.1245/s10434-012-2779-3. Epub 2012 Dec 1.

PMID:
23208132
31.

Sentinel lymph node biopsy in melanoma.

Boland GM, Gershenwald JE.

Cancer J. 2012 Mar-Apr;18(2):185-91. doi: 10.1097/PPO.0b013e31825046c7. Review.

PMID:
22453020
32.

Activation of PI3K signaling in Merkel cell carcinoma.

Nardi V, Song Y, Santamaria-Barria JA, Cosper AK, Lam Q, Faber AC, Boland GM, Yeap BY, Bergethon K, Scialabba VL, Tsao H, Settleman J, Ryan DP, Borger DR, Bhan AK, Hoang MP, Iafrate AJ, Cusack JC, Engelman JA, Dias-Santagata D.

Clin Cancer Res. 2012 Mar 1;18(5):1227-36. doi: 10.1158/1078-0432.CCR-11-2308. Epub 2012 Jan 18.

33.
34.

Formation and prevention of postoperative abdominal adhesions.

Boland GM, Weigel RJ.

J Surg Res. 2006 May;132(1):3-12. Epub 2006 Feb 2. Review. No abstract available.

PMID:
16457846
35.

Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells.

Boland GM, Perkins G, Hall DJ, Tuan RS.

J Cell Biochem. 2004 Dec 15;93(6):1210-30.

PMID:
15486964

Supplemental Content

Loading ...
Support Center